natgillin/translations-raw huggingface dataset:
CYP3A4 substrates and co-administration with
substrati za CYP3A4 in njihova sočasna
CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)) should therefore be administered with caution in patients receiving lenvatinib.
Substrate CYP3A4, za katere je znano, da imajo ozek terapevtski indeks (npr. astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil ali ergot alkaloide (ergotamin, dihdroergotamine) je treba zato pri bolnikih, ki prejemajo lenvatinib, previdno uporabljati.
CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)) should therefore be administered with caution in patients receiving lenvatinib.
Substrate CYP3A4, za katere je znano, da imajo ozek terapevtski indeks (npr. astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil ali ergot alkaloidi (ergotamin, dihidroergotamin)) je treba zato pri bolnikih, ki prejemajo lenvatinib, previdno uporabljati.
CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).
Previdnost je potrebna pri uporabi imatiniba z zaviralci proteaze, anolnimi antimikotiki, določenimi makrolidi (glejte poglavje 4.5), s substrati CYP3A4 z ozkim terapevtskim oknom (na primer s ciklosporinom, pimozidom, takrolimusom, sirolimusom, ergotaminom, diergotaminom, fentanilom, alfentanilom, terfenadinom, bortezomibom, docetakselom, kinidinom) ali z varfarinom in drugimi derivati kumarina (glejte poglavje 4.5).
CYP3A4 substrates with narrow therapeutic index
Substrati za CYP3A4 z ozkim terapevtskim indeksom
CYP3A4 was the major CYP isoenzyme involved in vitro in the metabolism of bedaquiline and the formation of the N-monodesmethyl metabolite (M2).
Encim CYP3A4 je najpomembnejši izoencim CYP, ki je vpleten v in vitro presnovo bedakilina in tvorbo N-monodesmetilnega presnovka (M2).
CYP3A4 were not involved in the metabolism of cysteamine bitartrate under the experimental conditions.
v eksperimentalnih pogojih nista sodelovala pri presnavljanju cisteaminijevega bitartrata.
CYP3A4, P-gp, BCRP inhibitors
Zaviralci CYP3A4, P-gp, BCRP
CYP3A4-inducing agents; or with renal or hepatic impairment
CYP3A4 ali z okvaro ledvic ali jeter
CYP3A4-metabolised and/or P-gp substrates known to prolong the QT interval may be contraindicated with Ketoconazole HRA, since the combination may lead to an increased risk of ventricular tachyarrhythmias, including occurrences of torsade de pointes, a potentially fatal arrhythmia (see section 4.3).
Zdravila, ki se presnavljajo prek CYP3A4, in/ali substrati P-gp, za katere je znano, da podaljšajo interval QT, so lahko kontraindicirani v kombinaciji z zdravilom Ketokonazol HRA, saj lahko sočasna uporaba povzroči povečano tveganje ventrikularnih aritmij, vključno s torsade de pointes, morebitno smrtno aritmijo (glejte poglavje 4.3).
CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.5).
CYP3A4/5 se je treba izogniti, razen če presodite, da morebitna korist odtehta tveganje (glejte poglavje 4.5).
CYP3A4/5 inhibitors have been shown to have a significant effect on the pharmacokinetics of guanfacine when co-administered.
Dokazali so, da zaviralci CYP3A4/5 signifikantno vplivajo na farmakokinetiko gvanfacina, če jih dajemo skupaj z njim.
CYP4A) and does not induce CYP1A2, CYP2C9 or CYP2C19 activities.
niti ne inducira delovanja CYP1A2, CYP2C9 ali CYP2C19.
Cyprus/ Κύπρος
Ciper/Κύπρος
Cyramza (N=236)
Zdravilo Cyramza (N=236)
Cyramza 10 mg/ml concentrate for solution for infusion
Cyramza 10 mg/ml koncentrat za raztopino za infundiranje
Cyramza as a single agent
Zdravilo Cyramza v monoterapiji
Cyramza at 10 mg/kg or placebo and docetaxel at 75 mg/m2 were each administered by intravenous infusion on day 1 of a 21-day cycle.
Zdravilo Cyramza v odmerku 10 mg/kg ali placebo in docetaksel v odmerku 75 mg/m2 so dajali z intravensko infuzijo na 1. dan 21-dnevnega cikla.
Cyramza contains the active substance ramucirumab.
Zdravilo Cyramza vsebuje zdravilno učinkovino ramucirumab.
Cyramza has been shown to increase survival of patients with advanced gastric or gastro-oesophageal junction cancer, metastatic colorectal cancer and advanced or metastatic non-small cell lung cancer whose disease has worsened despite treatment with other medicines in 4 main studies.
Štiri glavne študije so pokazale, da zdravilo Cyramza podaljša čas preživetja bolnikov z napredovalim rakom želodca ali rakom gastro-ezofagealnega prehoda, metastatskim kolorektalnim rakom, napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih se je bolezen poslabšala kljub zdravljenju z drugimi zdravili.
Cyramza has no known influence on the ability to drive and use machines.
Zdravilo Cyramza nima znanega vpliva na sposobnost vožnje in upravljanja s stroji.
Cyramza in combination with paclitaxel
Zdravilo Cyramza v kombinaciji s paklitakselom
Cyramza is a cancer medicine that contains the active substance ramucirumab, which is a monoclonal antibody.
Cyramza je zdravilo proti raku, ki vsebuje zdravilno učinkovino ramucirumab, ki je monoklonsko protitelo.
Cyramza is a cancer medicine used to treat adult patients with:
Zdravilo Cyramza je zdravilo za zdravljenje raka, ki se uporablja pri odraslih bolnikih:
Cyramza is a concentrate for solution for infusion (also called “sterile concentrate”).
Zdravilo Cyramza je koncentrat za raztopino za infundiranje (imenovan tudi »sterilni koncentrat«).
Cyramza is available as a concentrate to be made up into a solution for infusion (drip) into a vein.
Zdravilo Cyramza je na voljo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Cyramza is available in packs of:
Zdravilo Cyramza je na voljo v pakiranjih po:
Cyramza is given in combination with paclitaxel, another anti-cancer medicine, for the treatment of advanced stomach cancer (or cancer of the junction between the oesophagus and the stomach) in adults whose disease has worsened after treatment with medicines to treat cancer.
Zdravilo Cyramza je mogoče dajati tudi v kombinaciji s paklitakselom, drugim zdravilom proti raku, za zdravljenje napredovalega raka želodca (vključno z rakom prehoda med požiralnikom in želodcem) pri odraslih, pri katerih je bolezen po zdravljenju z zdravili proti raku napredovala.
Cyramza is used in combination with another medicine, paclitaxel, or on its own if the combination with paclitaxel is not appropriate, in patients whose disease has worsened despite treatment with medicines containing platinum or fluoropyrimidines; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Cyramza se uporablja v kombinaciji z drugim zdravilom, paklitakselom, ali samostojno, če kombinacija s paklitakselom ni primerna, pri bolnikih, pri katerih se je bolezen poslabšala kljub zdravljenju z zdravili, ki vsebujejo platino ali fluoropirimidine; metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Cyramza is used in combination with docetaxel in patients whose disease has worsened despite treatment with medicines containing platinum.
Zdravilo Cyramza se uporablja v kombinaciji z docetakselom pri bolnikih, pri katerih se je bolezen poslabšala kljub zdravljenju z zdravili, ki vsebujejo platino.
Cyramza is used with ‘FOLFIRI’ chemotherapy (a combination of fluorouracil, folinic acid and irinotecan) in patients whose disease has worsened despite treatment with bevacizumab, oxaliplatin and a fluoropyrimidine; non-small cell lung cancer that is advanced or has spread to other parts of the body.
Zdravilo Cyramza se uporablja skupaj s kemoterapijo FOLFIRI (kombinacijo fluoroacila, folinske kisline in irinotekana) pri bolnikih, pri katerih se je bolezen poslabšala kljub zdravljenju z bevacizumabom, oksaliplatinom in fluoropirimidinom; nedrobnoceličnega pljučnega raka, ki je napredoval ali se je razširil na druge dele telesa.
Cyramza N=238
zdravilo Cyramza N=238
Cyramza plus
Cyramza in
Cyramza plus docetaxel (N=627)
Cyramza in docetaksel (N = 627)
Cyramza plus docetaxel N=628
Zdravilo Cyramza in docetaksel
Cyramza plus FOLFIRI N=536
Cyramza in FOLFIRI N = 536
Cyramza plus paclitaxel (N=327)
Zdravilo Cyramza in paklitaksel (N=327)
Cyramza plus paclitaxel N=330
zdravilo Cyramza in paklitaksel N=330
Cyramza treatment will be temporarily stopped if you:
Zdravljenje z zdravilom Cyramza bo začasno prekinjeno
Cyramza was also shown to prolong survival of patients with colorectal and non-small cell lung cancer.
Zdravilo Cyramza je tudi podaljšalo življenje bolnikom s kolorektalnim in nedrobnoceličnim pljučnim rakom.
Cyramza will be permanently stopped if you develop a blood clot in your arteries.
Če v vaših venah nastane krvni strdek, bo zdravljenje z zdravilom Cyramza trajno prekinjeno.
Cyramza will be permanently stopped if you develop a fistula.
Če se pri vas pojavi fistula, bo zdravljenje z zdravilom Cyramza trajno prekinjeno.
Cyramza will be permanently stopped if you develop a hole in the wall of your gut.
Če v vaši črevesni steni nastane luknjica, bo zdravljenje z zdravilom Cyramza trajno prekinjeno.
Cyramza will be permanently stopped if you experience a severe infusion-related reaction.
Če se pri vas pojavi huda reakcija, povezana z infuzijo, bo zdravljenje z zdravilom Cyramza trajno prekinjeno.
Cyramza will be permanently stopped if you experience severe bleeding.
Če se pri vas pojavi huda krvavitev, bo zdravljenje z zdravilom Cyramza trajno prekinjeno.
Cyramza+Paclitaxel 330
Placebo+Paclitaxel 335
Cyst formation in your pancreas
nastanek ciste na trebušni slinavki
Cyst formation in your pancreas
nastanek ciste v trebušni slinavki,
Cyst in the kidney
cista na ledvicah,
Cystadane 1 g oral powder
Zdravilo Cystadane 1 g peroralni prašek
Cystadane is a powder for oral use that contains the active substance betaine anhydrous.
Zdravilo Cystadane je peroralni prašek, ki vsebuje zdravilno učinkovino brezvodni betain.
Cystadane is a white crystalline free flowing powder.
Zdravilo Cystadane je bel kristalen sipki prašek.
Cystadane is supplied with 3 measuring spoons to measure 100 mg, 150 mg and 1 g of the powder.
Zdravilo Cystadane se dobavlja s 3 merilnimi žličkami za odmerjanje 100 mg, 150 mg in 1 g praška.
Cystadane is used in patients with all three known types of homocystinuria, caused by a lack of the substances required for the breakdown of methionine (‘cystathionine beta-synthase’ [CBS] or ‘5,10- methylene-tetrahydrofolate reductase’[MTHFR]), or by defects in ‘cobalamin cofactor metabolism’ (cbl).
Zdravilo Cystadane se uporablja pri bolnikih z vsemi tremi znanimi tipi homocistinurije, ki so posledica pomanjkanja snovi, potrebnih za razgradnjo metionina (cistationin beta-sintaze [CBS] ali 5,10-metilentetrahidrofolat reduktaze [MTHFR]), ali napake v presnovi kofaktorjev kobalamina (cbl).
Cystadane is used to treat homocystinuria.
Zdravilo Cystadane je namenjeno za zdravljenje homocistinurije.
Cystadane should not be used by patients who may be hypersensitive (allergic) to betaine.
Zdravila Cystadane se ne sme uporabljati pri bolnikih, ki utegnejo biti preobčutljivi za (alergični na) betain.
Cystagon 150 mg: white, opaque hard capsules with CYSTAGON 150 on the body and MYLAN on the cap.
Cystagon 150 mg: bele, neprosojne trde kapsule z napisom CYSTAGON 150 na spodnjem delu in MYLAN na zgornjem delu.
Cystagon 50 mg: white, opaque hard capsules with CYSTA 50 on the body and MYLAN on the cap.
Cystagon 50 mg: bele, neprosojne trde kapsule z napisom CYSTA 50 na spodnjem delu in MYLAN na zgornjem delu.
CYSTAGON has minor or moderate influence on the ability to drive and use machines
CYSTAGON ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
CYSTAGON has minor or moderate influence on the ability to drive ans use machines
CYSTAGON ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
CYSTAGON has not been shown to prevent cystine crystals accumulating in the eye.
Ni dokazano, da bi CYSTAGON preprečeval kopičenje cistinskih kristalov v očesu.
CYSTAGON may cause drowsiness.
CYSTAGON lahko povzroča zaspanost.
CYSTAGON must not be used during breast-feeding.
Zdravila CYSTAGON med dojenjem ne smete uporabljati.
CYSTAGON should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.6 and section 5.3 as it is teratogenic in animals.
CYSTAGON se ne sme uporabljati med nosečnostjo, zlasti pa ne v prvem trimesečju, razen če to ni absolutno nujno (glejte poglavje 4.6 ter poglavje 5.3), ker se je pri živalih izkazal kot teratogen.
Cysteamine (mercaptamine bitartrate)
cisteamin (merkaptaminijev bitartrat)
Cysteamine bitartrate (CYSTAGON) is bioequivalent to cysteamine hydrochloride and phosphocysteamine.
Cisteaminijev bitartrat (CYSTAGON) je bioekvivalenten cisteaminijevemu kloridu in fosfocisteaminu.
Cysteamine has minor or moderate influence on the ability to drive and use machines.
Cisteamin ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function studies.
Cisteamin so občasno povezali z reverzibilno levkopenijo in nenormalnim delovanjem jeter.
Cystic fibrosis is an inherited disease that mainly affects the cells that secrete mucus in the lungs, and the cells that secrete digestive juices from the glands in the gut and pancreas.
Cistična fibroza je dedna bolezen, ki najbolj prizadene celice v pljučih, ki izločajo sluz, ter celice v trebušni slinavki in žlezah v črevesju, ki izločajo prebavne sokove.
Cystic fibrosis is caused by mutations in the CFTR gene.
Cistično fibrozo povzroča mutacija v genu CFTR.
Cystic fibrosis is caused by mutations of the CFTR gene.
Cistično fibrozo povzročajo mutacije v genu CFTR.
Cystinosis is a metabolic disease called ‘nephropathic cystinosis’ which is characterized by an abnormal accumulation of the amino acid cystine in various organs of the body such as the kidney, eye, muscle, pancreas, and brain.
Cistinoza je presnovna bolezen, ki se imenuje ‘nefropatska cistinoza’ in za katero je značilno nenormalno kopičenje aminokisline cistina v različnih telesnih organih, npr. ledvicah, očeh, mišicah, trebušni slinavki in možganih.
Cystitis haemorrhagic
hemoragični cistitis
Cystitis,
virusni
Cystitis, vaginitis, oral candidiasis
cistitis, vaginitis, kandidoza v ustih
Cystocele, endometrial disorder, endometrial hypertrophy* (sonographic endometrial thickness), uterine polyp, vaginal discharge, vaginal disorder
cistokela, bolezni endometrija, hipertrofija endometrija* (ultrazvočno ugotovljena zadebelitev endometrija), maternični polip, izcedek iz nožnice, bolezni nožnice
Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
cistoidni makularni edem (otekanje mrežnice v očesu, ki povzroča slabšanje vida),
Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision)
cistoidni makularni edem (oteklina mrežnice, ki privede do poslabšanja vida),
Cystoid macular oedema has been uncommonly reported (≥1/1,000 to <1/100) following treatment with bimatoprost 0.3 mg/ml eye drops, solution.
Občasno (≥1/1.000 do <1/100) so poročali o cistoidnem makularnem edemu kot posledici zdravljenja z bimatoprostom 0,3 mg/ml, kapljicami za oko, raztopino.
Cystoid Macular Oedema is considered to be a more severe subtype of macular oedema and currently only ‘macular oedema’ listed in the SmPC.
Cistoidni makularni edem se šteje kot hujša podvrsta makularnega edema in v sedanjem SmPC je naveden samo ‘makularni edem’.
cystoid macular oedema, eye swelling, vision blurred
cistoidni makularni edem, otekanje oči, zamegljen vid
cystoid macular oedema, vision blurred
cistoidni makularni edem, zamegljen vid
Cysts in the lining of joints (synovial cysts)
cista sklepne ovojnice (sinovialna cista)
Cytarabine (n = 99 cycles)
citarabin (n = 99 krogov)
Cytarabine and methotrexate patients not completing all 4 doses are counted as a fraction of a cycle.
Bolniki, ki niso prejeli vseh 4 odmerkov citarabina, so se šteli kot zaključen krog zdravljenja.
Cytarabine caused the transformation of hamster embryo cells and rat H43 cells in vitro.
Citarabin je povzročil transformacijo embrionalnih celic hrčka in podganjih celic H43 in vitro.
Cytarabine is a cell-cycle phase specific antineoplastic agent, affecting cells only during the S-phase of cell division.
Citarabin je zdravilo z delovanjem na novotvorbe, specifično za celični ciklus, ki vpliva samo na celice v fazi S celične delitve.
Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.
V celičnih kulturah je citarabin toksičen za številne vrste delečih se celic sesalcev.
Cytarabine patients not completing all 4 doses within a cycle are counted as a complete cycle.
Bolniki, ki niso prejeli vseh 4 odmerkov citarabina, so se šteli kot zaključen krog zdravljenja.
Cytarabine, the active ingredient in DepoCyte, can cause foetal harm when administered systemically during pregnancy, mainly during the first trimester.
Citarabin, zdravilna učinkovina v zdravilu DepoCyte, lahko pri sistemski uporabi med nosečnostjo škoduje plodu, predvsem v prvem trimestru.
Cytarabine, when administered intrathecally, has been associated with nausea, vomiting and serious central nervous system toxicity which can lead to a permanent deficit, this includes blindness, myelopathy and other neurological toxicity.
Za intratekalno uporabo citarabina so značilni slabost, bruhanje in huda toksičnost osrednjega živčevja, ki lahko povzroči trajni nevrološki izpad, vključno s slepoto, mielopatijo in drugimi nevrotoksičnimi učinki.
Cytochrome (CYP) 450-mediated metabolic interactions are not anticipated as decitabine metabolism is not mediated by this system but by oxidative deamination.
Metaboličnih interakcij zaradi presnove s citokromom (CYP) 450 ni pričakovati, saj se decitabin ne presnavlja s tem encimskim sistemom, ampak z oksidativno deaminacijo.
Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.
Aktivnost citokroma P450 CYP 2C9 je manjša pri posameznikih z genetskim polimorfizmom, ki zmanjšuje aktivnost encima, npr. pri tistih s homozigotnostjo za polimorfizem CYP2C9*3.
Cytochrome P450 enzymes as well as conjugation reactions are not involved in the metabolism of efalizumab.
Citokrom P450 encimi in reakcije konjugacije ne sodelujejo pri presnovi efalizumaba.
Cytochrome P450 Inhibition
Zaviranje citokroma P450
Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokroma P450-CYP1A2 in P450- CYP2D6 prispevata k tvorbi N-demetilnih in 2-hidroksimetilnih metabolitov, oboji so v študijah na živalih pokazali pomembno manj farmakološke aktivnosti in vivo kot olanzapin.
Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients.
Citogenetske nepravilnosti so pregledali pri 117 bolnikih od celotne populacije 176 bolnikov.
Cytogenetic confirmation of conversion to a normal genotype and Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) detection of PML/RAR conversion to normal are shown in the table below.
Citogenetska potrditev pretvorbe v normalen genotip in odkrivanje pretvorbe PML/RAR v običajno obliko z metodo polimerazne verižne reakcije z reverzno transkriptazo (RT-PCR - »reverse transcriptase – polymerase chain reaction«) je prikazana v tabeli spodaj.
Cytogenetic response
Citogenetični odziv
Cytogenetic Response
Citogenetski odgovor
Cytogenetic Response (%)
citogenetični odziv (%)
Cytogenetic response criteria: complete (0% Ph+ metaphases), partial (1–35%), minor (36–65%) or minimal (66–95%).
Kriteriji citogenetičnega odziva: popolni (0 % Ph+ metafaz), delni (1–35 %), manjši (36–65 %) ali minimalni (66–95 %).
Cytogenetic Response criteria: Major Cytogenetic response included Complete (0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridization [FISH]) or partial (1%-35%) cytogenetic responses.
Merila za citogenetični odziv: pomembni citogenetični odziv je vključeval popolne (0 % Ph+ metafaz iz kostnega mozga ali < 1 % pozitivnih celic iz fluorescenčne “in situ” hibridizacije [FISH]) ali delne (1 %-35 %) citogenetične odzive.
Cytogenetic response within 12 months
Citogenetski odziv v 12 mesecih
Cytogenetic responsec (%) (95% CI)
Citogenetski odzivc (%) (95% IZ)
Cytogenetics after TRISENOX therapy
Citogenetika po zdravljenju z zdravilom TRISENOX
Cytokine release related symptoms with higher intensities
Simptomi večje intenzitete, povezani s sproščanje citokina
Cytokine release syndrome
indrom sproščanja
Cytokine release syndrome
sindrom sproščanja citokinov
Cytokine release syndrome (CRS) which may be life-threatening or fatal (grade ≥ 4) has been reported in patients receiving BLINCYTO (see section 4.8).
Med zdravljenjem z zdravilom BLINCYTO so poročali o sindromu sproščanja citokinov (CRS – cytokine release syndrome), ki je lahko smrtno nevaren ali smrten (≥ 4. stopnja) (glejte poglavje 4.8).
Cytokine release syndrome*, hypersensitivity*.
Sindrom sproščanja citokina*, preobčutljivost
Cytokine release syndrome*, rigors*, chills*, hyperhidrosis*, fatigue*
sindrom sproščanja citokinov*, mrzlica z drgetanjem*, hiperhidroza*, utrujenost
Cytokine release syndromea
indrom sproščanja citokinova
Cytokine storm Hypersensitivity
citokinski vihar preobčutljivost
Cytokine-refractory metastatic renal cell carcinoma
Proti citokinom odporni metastatski karcinom ledvičnih celic (MRCC)
Cytokines are proteins made by your body that co- ordinate communication between cells and help control cell activity.
Citokini so beljakovine, ki jih izdeluje vaše telo, ki uravnavajo komuniciranje med celicami in pomagajo kontrolirati celično aktivnost.
cytolytic hepatitis, liver function test abnormal
citolitični hepatitis, nenormalni izvidi testov delovanja jeter
Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.
Profilaksa proti citomegalovirusu (CMV) je priporočljiva prve 3 mesece po presaditvi, posebno pri bolnikih z zvečanim tveganjem bolezni CMV.
Cytomegalovirus (CMV), a virus that can cause serious tissue and blood infections
Citomegalovirus lahko povzroči hude okužbe tkiv in krvi.
cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus†
Okužba s citomegalovirusom, reaktivacija okužb, kot sta okužbi s citomegalovirusom, z virusom hepatitisa B
cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus†
okužba s citomegalovirusom, reaktivacija okužbe, npr. citomegalovirus, virus hepatitisa B
Cytopaenias including pancytopaenia have been infrequently reported with Simponi in clinical trials.
O posameznih vrstah citopenije in pancitopeniji pa so v kliničnih preskušanjih z zdravilom Simponi poročali le redko.
Cytotoxic
Citostatik
Cytotoxic
CITOTOKSIČNO
CYTOTOXIC
CITOTOKSIČNO ZDRAVILO
Cytotoxic
citotoksično zdravilo
Cytotoxic
Citotoksično zdravilo.
Cytotoxic agents
Citotoksične zdravilne učinkovine
Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because in addition to cancer cells it also kills other fast growing cells such as neutrophils, leaving the patient at risk of infections.
Citotoksična kemoterapija (zdravila, ki uničijo hitro rastoče celice) pogosto povzroči nevtropenijo, ker poleg rakavih celic uniči tudi druge hitro rastoče celice, kot so nevtrofilci, zaradi česar je bolnik izpostavljen tveganju za okužbe.
cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide.
citotoksična zdravila (za zdravljenje raka), kot sta metotreksat ali ciklofosfamid,